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Abstract (125 max) 
Dendritic cells (DC) are professional antigen-presenting cells that orchestrate immune 
responses. The human DC population comprises two main functionally-specialized lineages, 
whose origins and differentiation pathways remain incompletely defined. Here we combine two 
high-dimensional technologies, single-cell mRNA sequencing and Cytometry by Time-of-Flight 
(CyTOF), to identify human blood CD123+CD33+CD45RA+ DC precursors (pre-DC). Pre-DC 
share surface markers with plasmacytoid DC (pDC) but have distinct functional properties that 
were previously attributed to pDC. Tracing the differentiation of DC from the bone marrow to 
the peripheral blood revealed that the pre-DC compartment contains distinct lineage-committed 
sub-populations including one early uncommitted CD123high pre-DC subset and two 
CD45RA+CD123low lineage-committed subsets exhibiting functional differences. The discovery 
of multiple committed pre-DC populations opens promising new avenues for the therapeutic 
exploitation of DC subset-specific targeting. 
 
One Sentence Summary: Mapping the human dendritic cell lineage 
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Introduction (4500 max including ref, notes and caption) 
Dendritic cells (DC) are professional pathogen-sensing and antigen-presenting cells that 
are central to the initiation and regulation of immune responses (1). The DC population is 
classified into two lineages: plasmacytoid DC (pDC), and conventional DC (cDC), the latter 
comprising cDC1 and cDC2 sub-populations (2, 3). Dissecting the origins and differentiation 
pathways giving rise to DC sub-populations is necessary to fully understand their homeostasis 
and role in immune responses, and for the development of DC subset-specific therapeutic 
interventions. Murine DC arise from unique DC-restricted bone-marrow (BM) progenitors, 
called common DC progenitors (CDP) that differentiate into pDC and DC precursors (pre-DC), 
which migrate out of the BM into peripheral tissues (4-7). Recently, human equivalents of 
murine CDP and pre-DC were described (8, 9); human pre-DC comprise ~0.001% of peripheral 
blood mononuclear cells (PBMC) and were identified by expression of cytokine receptors that 
both mark and drive DC differentiation in mice, including CD117 (c-kit, SCF), CD116 
(GMCSF-R, Granulocyte-macrophage colony-stimulating factor receptor), CD135 (FLT3, FMS-
like tyrosine kinase 3) and CD123 (IL3-Rα) (9). Interestingly, some studies have observed 
similar receptor expression patterns within human pDC populations, which can differentiate into 
cDC-like cells when stimulated with IL-3 and CD40L (10, 11): therefore either pDC are 
precursors of cDC, as proposed (11), or the conventionally-defined pDC population is 
heterogeneous, incorporating an independent pre-DC sub-population. 
Human blood and tissue DC, and their precursors in the BM, are identified by expression 
of CD135 and HLA-DR (12-14). Hence, we interrogated the CD135+HLA-DR+ fraction of 
human blood using several integrated high-dimensional analysis techniques (single-cell mRNA 
sequencing or scmRNAseq; microfluidic single cell mRNA sequencing and mass cytometry 
using Cytometry by Time-of-Flight mass spectrometry or CyTOF). These approaches supersede 
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traditional surface marker-based approaches, and identified a novel population of pre-DC within 
the conventionally-defined pDC population. These pre-DC possess a unique phenotype and 
distinct functional properties that were previously attributed to pDC. Extending our analysis to 
all DC populations in human blood and BM, we identified the entire DC lineage arising from the 
BM, and revealed the transcriptional priming of pre-DC towards distinct DC subsets. These data 
offer new insights into DC heterogeneity and ontogeny, and highlight unexplored avenues for 
investigation of the therapeutic potential of DC subset-specific targeting.  
 
Results 
Unbiased identification of DC precursors by non-supervised single cell RNAseq and CyTOF 
Using PBMC isolated from human blood, we first employed massively-parallel single 
cell mRNA sequencing (MARS-seq) (15) to transcriptionally profile 710 individual cells within 
the lineage- (CD3/CD14/CD16/CD20/CD34) negative, HLA-DR+CD135+ population (Fig. 1A-
E; see Fig. S1A for sorting strategy, Fig. S1B-F for workflow & quality control and Table S3 for 
gene expression data). MARS-seq data were processed using non-linear dimensionality reduction 
via t-stochastic neighbor embedding (tSNE), which enables unbiased visualization of high-
dimensional similarities of cells in a two-dimensional map (16-18). Density-based spatial 
clustering of applications with noise (DBSCAN) on the tSNE dimensions revealed 5 distinct 
clusters of transcriptionally-related cells within the selected PBMC population (Fig. 1A, S1G). 
To define the nature of these clusters, we generated gene signature scores for pDC, cDC1 and 
cDC2, and overlaid the expression of these signatures by each cell onto the tSNE visualization. 
Clusters #1 and #2 were identified as pDC, cluster 3 as cDC1, and cluster 5 as cDC2. The last 
cluster (#4) laid in between the cDC1 (#3) and cDC2 (#5) clusters and possessed a weak mixed 
pDC/cDC signature (Fig. 1A). We then applied connectivity MAP (cMAP) analysis (19), which 
calculates the degree of enrichment for transcripts of pDC or cDC signature genes in each 
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individual cell; this approach confirmed the signatures of pDC (#1 and #2) and cDC (#3 and #5) 
clusters, and showed that most cells in cluster #4 expressed a cDC signature (Fig. 1B). The 
Mpath algorithm (20) was then applied to the 5 clusters defined in the tSNE analysis to identify 
hypothetical developmental relationships based on these transcriptional similarities between cells 
(Fig. 1C). Mpath revealed that the 5 clusters were grouped into 3 distinct branches with one 
central cluster (cluster #4) at the intersection of the 3 branches (Fig. 1C, S2A). To confirm these 
findings, we employed the Monocle algorithm (21) and principal component analyses (PCA), 
which similarly resolved the cells into the same 3 branches with the same subset identities, and 
again with the cells from tSNE cluster #4 falling at their intersection (Fig. 1D, S2B). While cells 
from pDC clusters (#1 and #2) had a higher expression of pDC-specific markers and 
transcription factors (TF) then the cDC clusters (#3 and #5) and central cluster #4, cells in cluster 
#4 expressed higher levels of markers and TF previously-associated with all cDC lineage (Fig. 
1E).. This phenotype led us to hypothesize that cluster #4 represented a population of putative 
intermediate uncommitted DC precursors. 
To further understand the delineated sub-populations, we employed CyTOF, which 
simultaneously measures the intensity of expression of up to 38 different molecules at the single 
cell level. We designed a panel of 38 antibodies (Table S2) recognizing DC lineage/progenitor-
associated surface molecules (Fig. 1F-H, S3), or molecules such as CD2, CX3CR1, CD11c and 
HLA-DR identified by MARS-seq as expressed by cluster #4 at the mRNA level (Fig. 1E). 
Using the tSNE algorithm, the CD45+Lineage-(CD7/CD14/CD15/CD16/CD19/CD34)HLA-DR+ 
PBMC fraction (see Fig. S3A for gating strategy) resolved into 3 distinct clusters representing 
cDC1, cDC2 and pDC (Fig. 1F), with an intermediate cluster at the intersection of the cDC and 
pDC clusters that expressed both cDC- (CD11c/CX3CR1/CD2/CD33/CD141/BTLA) and pDC- 
(CD45RA/CD123/CD303) associated markers (Fig. 1G-H, S3B), corresponding to the MARS-
seq cluster #4. The delineation of these clusters was confirmed by phenograph unsupervised 
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clustering (Fig. S3C). The location of this cluster of CD123+CD33+ cells suggested again a 
distinct and intermediate nature; cells here showed the highest expression of CD5, CD327, 
CD85j, along with high levels of HLA-DR and the cDC-associated molecule CD86 (Fig. 1H-I). 
Taken together, these characteristics led us to ask whether CD123+CD33+ cells might represent 
circulating human pre-DC. 
Pre-DC exist within the pDC fraction and give rise to cDC 
We further analyzed the CD123+CD33+ cell cluster within the Lin-HLA-DR+ fraction of 
PBMC by flow cytometry, where we identified CD123+CD33- pDC (blue), CD45RA+/-CD123- 
cDC1 (red) and cDC2 (beige), as well as CD33+CD45RA+CD123+ putative pre-DC (purple) 
(Fig. 2A, S4A). Putative pre-DC expressed CX3CR1, CD2, CD303 and CD304, with low CD11c 
expression, while CD123+CD33- pDC exhibited variable CD2 expression (Fig. 2A-B, S4B-C). 
Extending our analysis to immune cells from the spleen, we identified a similar putative pre-DC 
population, which was more abundant than in blood and expressed higher levels of CD11c (Fig. 
2A, 2C, S4D). Both putative pre-DC populations in blood and spleen also expressed CD135 and 
intermediate levels of CD141 (Fig. S4C). Wright-Giemsa staining of putative pre-DC sorted 
from blood revealed an indented nuclear pattern reminiscent of classical cDC, accompanied by a 
perinuclear area of clearing and basophilic cytoplasm reminiscent of pDC (Fig. 2D). At the ultra-
structural level, putative pre-DC and pDC exhibited distinct features, despite their morphological 
similarities (Fig. 2E, S4E): where putative pre-DC possessed an indented nuclear pattern, a large 
nucleus and lesser cytosol, pDC contained a smaller nucleus, abundant cytosol and numerous 
stacks of rough ER membranes decorated with ribosomes, suggesting a developed secretory 
apparatus in agreement with published data (22). 
We then compared the differentiation capacity of pre-DC to that of cDC and pDC 
through stromal culture with FLT3L, GM-CSF and SCF, as described (8). After 5 days, while 
pDC, cDC1 and cDC2 populations predominantly remained in their initial states, the putative 
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pre-DC population differentiated into cDC1 and cDC2 in the proportions found in vivo (14, 23-
25) (Fig. 2F, S4F, S5). Altogether, these data suggested that 
CD123+CD33+CD45RA+CX3CR1+CD2+ cells are circulating pre-DC with cDC differentiation 
potential. Recently, Breton and colleagues reported a minor population of human pre-DC (9), 
highlighted in Fig. S6A (blue), sharing a similar phenotype with the Lin-
CD123+CD33+CD45RA+ pre-DC (pink) defined here (Fig. S6A-B). However, our approach 
extends their findings and reveals that the pre-DC population in blood and spleen is significantly 
larger than that identified within the minor CD303-CD141-CD117+ fraction considered 
previously (Fig. S6C-D).  
 
Pre-DC are functionally distinct from pDC  
IFNα-secreting pDC can differentiate into cells resembling cDC when cultured with IL-3 
and CD40L (10, 11), and were considered DC precursors (11). However, when we used 
traditional ILT3+ILT1- (10) or CD4+CD11c- (11) pDC gating strategies, we detected a 
“contaminating” CD123+CD33+CD45RA+ pre-DC sub-population within both groups that were 
previously considered pure pDC (Fig. S6E-F). Therefore, we questioned whether other properties 
of traditionally-classified “pDC populations” might be attributed to pre-DC. Stimulation of either 
Toll-like receptor (TLR)7/8 (CL097) or TLR9 (CpG ODN 2216) resulted in abundant secretion 
of IFNα but not IL-12p40 by pure cultures of pDC, whereas pre-DC readily secreted IL-12p40 
but not IFNα (Fig. 2G, S7). Furthermore, while pDC were thought to induce proliferation of 
naïve CD4+ T cells (10, 26), this capacity too lies solely within the pre-DC sub-population (Fig. 
2H). Therefore reports of potent allostimulatory capacity and IL-12p40 production by CD2+ pDC 
(26) might also be explained by CD2+ pre-DC contamination (27) (Fig. S6G). Pitt-hopkins 
syndrome (PHS), characterized by abnormal craniofacial and neural development, severe mental 
retardation, and motor dysfunction, is caused by an haplo-insufficiency in the TCF4 gene which 
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encodes the E2-2 transcription factor, a central regulator of pDC development (28). We 
confirmed that PHS patients had a strong reduction in their blood pDC numbers and found that 
they retained a population of pre-DC (Fig. 2I, S4G), likely accounting for the previously ill-
understood CD45RA+CD123+CD303lo population detected in these patients (29). Taken 
together, our data indicate that, while pre-DC and pDC share some phenotypic features, they can 
be separated by differential expression of several markers including CD33, CX3CR1, CD2, CD5 
and CD327: pDC are the bona fide IFNα-producing cells, but the reported IL-12 production and 
CD4+ T cell allostimulatory capacity of pDC can likely be attributed to “contaminating” pre-DC, 
which can give rise to both cDC1 and cDC2. 
 
Identification and characterization of committed pre-DC subsets 
The murine pre-DC population contains both uncommitted and committed pre-cDC1 and 
pre-cDC2 precursors (7). We asked whether the same was true for human blood pre-DC using 
microfluidic scmRNAseq (see Fig. S8A for sorting strategy, Fig. S8B-C for workflow & quality 
control, Table S4 for gene expression data). The additional gene expression data relative to the 
MARS-seq strategy used for Fig. 1A-F (2.5 million reads/cell vs 60,000 reads/cell, respectively) 
was subjected to cMAP analysis, which calculated the degree of enrichment for cDC1 or cDC2 
signature gene transcripts for each single cell (Fig. 3A). Among the 92 pre-DC analyzed, 19 and 
20 cells exhibited enrichment for cDC1 and cDC2 gene expression signatures, respectively, and 
53 cells showed no transcriptional similarity with either cDC subset. Further Mpath analysis 
showed that these “unprimed” pre-DC were developmentally related to cDC1- and cDC2- 
primed pre-DC, and thus their patterns of gene expression fell between the cDC1 and cDC2 
signature scores by cMAP (Fig. 3B, S9). These data suggest that the human pre-DC population 
contains cells exhibiting transcriptomic priming towards cDC1 and cDC2 lineages, as seen 
previously in mice (7). 
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We next asked whether we could identify this evident heterogeneity within the pre-DC 
population by flow cytometry, using either pre-DC-specific markers (CD45RA, CD327, CD5) or 
those expressed relatively higher by pre-DC compared to cDC2 (BTLA, CD141). 3D-PCA 
analysis of the Lin-HLA-DR+CD33+ population (containing both differentiated cDC and pre-DC) 
revealed 3 major cell clusters: CADM1+ cDC1 (red region), CD1c+ cDC2 (beige region) and 
CD123+ pre-DC (purple region) (Fig. 3C, S10A). Interestingly, while cells located at the 
intersection of these 3 clusters (black dashed oval region in Fig. 3D) expressed lower levels of 
CD123 than pre-DC (though higher levels than differentiated cDC, Fig. 3C), they also expressed 
high levels of pre-DC markers (Fig. 3D, S10A). We reasoned that these CD45RA+CD123lo cells 
might be committed pre-DC differentiating into either cDC1 or cDC2 (Fig. 3E, where cells 
falling in regions defined in Fig. 3C-D are overlaid). The wanderlust algorithm (30), which 
orders cells according to their most immature to mature state into a constructed trajectory, 
confirmed the developmental relationship between pre-DC (early events, dark), 
CD45RA+CD123lo cells (intermediate events, grey) and mature cDC (clear) (Fig. 3F). Flow 
cytometry of PBMC allowed the identification of CD123+CADM1-CD1c- putative uncommitted 
pre-DC, alongside putative CADM1+CD1c- pre-cDC1 and CADM1-CD1c+ pre-cDC2 within the 
remaining CD45RA+ cells (Fig. 3G, S10B). These 3 populations were also present, and more 
abundant, in the spleen (Fig. S10C). Importantly, in vitro culture of pre-DC subsets sorted from 
PBMC did not give rise to any CD303+ cells (which would be either undifferentiated pre-DC or 
differentiated pDC), while instead early pre-DC gave rise to both cDC subsets, and pre-cDC1 
and pre-cDC2 differentiated exclusively into cDC1 and cDC2 subsets, respectively (Fig. 3H, 
S10D, S11). 
Scanning electron microscopy confirmed that early pre-DC are larger and rougher in 
appearance than pDC, and revealed that committed pre-DC subsets closely resembled their 
mature cDC counterparts (Fig. 3I, S10E). Flow cytometry phenotyping of blood pre-DC (Fig. 
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S10F) identified patterns of transitional marker expression characterized by progressive 
evolution throughout the development of early pre-DC towards pre-cDC1/2 and differentiated 
cDC1/2: CD45RO and CD33 were acquired in parallel with the loss of CD45RA; CD5, CD123, 
CD304 and CD327 were expressed abundantly by early pre-DC, intermediately by pre-cDC1 and 
pre-cDC2, and rarely if at all by mature cDC and pDC; FcεRI and CD1c were acquired as early 
pre-DC commit towards the cDC2 lineage, concurrent with the loss of BTLA and CD319 
expression; early pre-DC had an intermediate expression of CD141 which dropped along cDC2 
differentiation but was increasingly expressed during commitment towards cDC1, with few pre-
cDC1 already starting to express Clec9A; and IRF8 and IRF4, transcription factors regulating 
cDC lineage development (2, 3), were expressed by early pre-DC and pre-cDC1, while pre-cDC2 
maintained only IRF4 expression (Fig. S10G). 
We next sorted pre-DC and DC subsets from blood and performed microarray analyses to 
define their entire transcriptome. 3D-PCA of microarray data showed that pDC were clearly 
separated from other pre-DC and DC subsets along the PC1 axis (Fig. 4A, S12). The PC2 axis 
indicated that cDC2 and pre-cDC2 exhibited similar transcriptomes, while pre-cDC1 occupied a 
position between early pre-DC and cDC1. Hierarchical clustering of differentially-expressed 
genes (DEG) confirmed the similarities between committed pre-DC and their corresponding 
mature subset (Fig. S13). The greatest number of DEG was found between early pre-DC and 
pDC (1249 genes) among which CD86, CD2, CD22, CD5, ITGAX (CD11c), CD33, CLEC10A, 
SIGLEC6 (CD327), THBD, CLEC12A, KLF4 and ZBTB46 were expressed by early pre-DC, 
while pDC showed expression of CD68, CLEC4C, TCF4, PACSIN1, IRF7 and TLR7 (Fig. 4B). 
An evolution of gene expression pattern was evident from early pre-DC, to pre-cDC1 and then 
cDC1 (Fig. 4C-D), while pre-cDC2 were similar to cDC2 (Fig. 4D, S13). Unsupervised gene 
expression analysis of all cDC and pre-DC subsets identified 62 commonly expressed genes 
including the transcription factors BATF3, ID2 and TCF4 (E2-2), and the pre-DC markers 
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CLEC4C (CD303), SIGLEC6 (CD327), and IL3RA (CD123) (Fig. 4E). During early pre-DC to 
cDC differentiation, the progressive reduction in transcript abundance of SIGLEC6 (CD327), 
CD22 and AXL is mirrored at the protein level (Fig. 4F). Key transcription factors involved in 
the differentiation and/or maturation of DC subsets showed a progressive change in their 
expression along the differentiation path from pre-DC to mature cDC (Fig. 4G). Finally, pathway 
analyses revealed that pre-DC exhibit an enrichment of cDC functions relative to pDC, and a 
relatively immature state compared to mature cDC (Fig. S14). 
 
Committed pre-DC subsets are functional 
We then asked to what extent the functional specializations of DC (1, 31) were acquired 
at the precursor level. We stimulated PBMC with TLR agonists and measured their cytokine 
production (Fig. 5A). Pre-DC produced markedly more TNFα and IL-12p40 following exposure 
to CL097 (TLR7/8 agonist) or CpG ODN 2216 (TLR9 agonist), than to LPS (TLR4 agonist) or 
polyI:C (TLR3 agonist). We confirmed that pDC were uniquely capable of robust IFN 
production in response to CL097 and CpG ODN 2216. CpG ODN 2216 stimulation also 
triggered IL-12p40 and TNFα production by early pre-DC, pre-cDC1, and to a lesser extent pre-
cDC2. Although TLR9 transcripts were detected only in early pre-DC (Fig. S15A), these data 
indicate that, contrary to differentiated cDC1 and cDC2, pre-cDC1 and pre-cDC2 do express 
functional TLR9 protein. Interestingly, while pre-cDC2 resembled cDC2 at the gene expression 
level, their TLR-responsiveness was intermediate between that of early pre-DC and cDC2. Pre-
DC subsets also expressed T cell costimulatory molecules (Fig. 5B) and induced proliferation 
and polarization of naïve CD4+ T cells to a similar level as mature cDC (Fig. 5C, S15B).  
 
Unsupervised mapping of DC ontogeny using scmRNAseq and CyTOF 
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We performed an unsupervised isoMAP analysis of human BM cells, obtained from 
CyTOF analysis, focusing on the Lin-CD123hi fraction (Fig. 6A, S16A). Such analysis 
automatically identified CD123hiCD34+ CDP (phenograph cluster #5), from which branched 
CD34-CD123+CD327+CD33+ pre-DC (clusters #1 and #2) or CD34-CD123+CD303+CD68+ pDC 
(clusters #3 and #4), both progressively acquiring their respective phenotypes; cells in the pre-
DC branch increasingly expressed CD2, CD11c, CD116 and, at a later stage, CD1c. In the 
peripheral blood, two parallel lineages, corresponding to either pre-DC or pDC were also evident 
in the isoMAP analysis of lineage-CD123+ cells, in which a CDP population was not detected 
(Fig. 6C). IsoMAP and phenograph analysis of pre-DC extracted from the isoMAP analysis of 
Fig. 6A (BM, clusters #1 and #2) and Fig. 6B (blood, cluster #6) revealed the 3 distinct pre-DC 
subsets (Fig. 6C as defined by their unique marker expression patterns (Fig. S16B-C). In 
summary, we were able to trace the developmental stages of DC from the BM to the peripheral 
blood through CyTOF. The CDP population in the BM bifurcates into two pathways, developing 
into either the pre-DC or pDC found in blood (Fig. 6A-C): the pre-DC population is 
heterogeneous and exists as distinct subsets detectable in both blood and BM (Fig. 6C, S16B-C). 
Alongside, we uncovered an intriguing heterogeneity in blood and BM pDC that warrants further 
investigation (Fig. 6C, S16D-E). 
 
 
Discussion 
Using unsupervised single-cell RNAseq and CyTOF analyses, we unraveled the 
complexity of the human DC lineage at the single cell level, revealing a continuous process of 
differentiation that starts in the BM with CDP, and diverges at the point of emergence of pre-DC 
and pDC potentials, with subsequent maturation of both lineages in the blood. A previous study 
using traditional surface marker-based approaches had suggested the presence of a minor pre-DC 
population in PBMC (9), but the combination of high-dimensional techniques and unbiased 
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analysis employed here revealed that this minor population had been significantly and 
importantly underestimated. Our data extended the published findings and revealed the existence 
of a population of pre-DC that overlapped with those observed by Breton and colleagues within 
the CD117+CD303-CD141- fraction of PBMC. However, we also showed that the full pre-DC 
population includes more than ten-fold the number of cells in peripheral blood than was 
originally estimated, and is considerably more diverse. 
 
Recent work in mice found uncommitted and subset-committed pre-DC subsets in BM 
(7, 32); similarly, we identified 3 functionally- and phenotypically- distinct pre-DC populations 
in human PBMC, spleen and BM: uncommitted pre-DC and 2 populations of subset-committed 
pre-DC. In line with the concept of continuous differentiation from the BM to the blood, the 
proportion of uncommitted cells was higher in the BM pre-DC population than in that of the 
blood. Altogether, these findings support a two-step model of DC development in which a 
central transcriptomic subset-specific program is imprinted on DC precursors from the CDP 
stage onwards, conferring a core subset identity irrespective of the final tissue destination; then 
in the second step, peripheral tissue-dependent programming is added to ensure site-specific 
functionality and adaptation (7, 32). Future studies will be required to reveal the molecular 
events underlying DC subset lineage priming, the tissue-specific cues that regulate peripheral 
programming as well as to design strategies that specifically target DC subsets at the precursor 
level. In addition, how the proportions of uncommitted pre-DC versus committed pre-DC are 
modified in acute and chronic inflammatory settings warrants further investigation. 
 
An important aspect of unbiased analysis is that cells are not excluded from consideration 
on the basis of preconceptions concerning their surface phenotype. In this case, we found that 
pre-DC express most of the markers classically used to define pDC, such as CD123, CD303 and 
CD304. Thus the phenotypic strategy used to identify and isolate pDC in many functional studies 
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has led to the inadvertent inclusion of CD123+CD33+ pre-DC within the pDC population. While 
this calls us to urgently reconsider some aspects of “pDC population” biology, it may also 
explain earlier findings, including reports suggesting that: pDC cultures possess cDC potential , 
acquiring cDC-like morphology (10, 11), also recently observed in murine BM pDC (33); pDC 
can mediate Th1 immunity through production of both IFNα and IL-12 (10, 34-38); pDC exhibit 
naïve T-cell allostimulatory capacity (26, 36); and that pDC express costimulatory molecules and 
exhibit antigen-presentation/cross-presentation capabilities at the expense of IFNα secretion (34, 
39). These observations could well be attributed to the undetected pre-DC in the pDC 
populations described by these studies; indeed it was speculated that the IL-12 production 
observed in these early studies might be due to the presence of contaminating CD11c+ cDC (40). 
Seeking clarification, we separated CX3CR1+CD33+CD123+CD303+CD304+ pre-DC from 
CX3CR1-CD33-CD123+CD303+CD304+ “pure” pDC and showed that pDC could not polarize 
nor induce proliferation of naïve CD4 T cells, while pre-DC were able to do so: pDC were 
unable to produce IL-12, unlike pre-DC, but were the only cells capable of strongly producing 
IFN in response to TRL7/8/9 agonists, as initially described (41). Thus, it is of paramount 
importance that pre-DC be excluded from pDC populations in future studies, particularly when 
using commercial pDC isolation kits. Finally, if pDC are now stripped of all their cDC 
properties, it raises the question of whether they truly belong to the DC lineage, or rather are a 
distinct type of innate IFN-I-producing lymphoid cell. Importantly, it also remains to be shown 
whether the BM CD34+CD123hi CDP population is also a mixture of independent bona fide cDC 
progenitors and pDC progenitors. 
 
Despite their classification as precursors, human pre-DC appear functional in their own 
right, being equipped with some T-cell co-stimulatory molecules, and with a strong capacity for 
naïve T cell allostimulation and cytokine secretion in response to TLR stimulation (Fig. 2, Fig. 5 
and S7, S14). Pre-DC produced low levels of IFN-α in response to CpG ODN 2216 exposure, 
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and secreted IL-12 and TNF-α in response to various TLR ligands. Hence, it is reasonable to 
propose that pre-DC have the potential to play a role in the context of disease, particularly in 
inflammatory and autoimmune diseases where dysregulation of their differentiation continuum 
or their arrested development could render them a potent source of inflammatory DC ready for 
rapid recruitment and mobilization. 
 
Beyond the identification of pre-DC, our data revealed unappreciated transcriptional and 
phenotypic heterogeneity within circulating mature DC populations. This was particularly clear 
in the case of cDC2 and pDC, which were grouped into multiple Mpath clusters in the single-cell 
RNAseq analysis, and showed marked dispersion in the tSNE analysis of CyTOF data with 
phenotypic heterogeneity. IsoMAP analysis of CyTOF data also revealed another level of pDC 
heterogeneity by illustrating the progressive phenotypic transition from CDP into CD2+ pDC in 
the BM, involving intermediate cells that could be pre-pDC. Whether a circulating pre-pDC 
population exists remains to be concluded.  Finally, defining the mechanisms that direct the 
differentiation of uncommitted pre-DC into cDC1, cDC2 or that could maintain these cells into 
their initial uncommitted state in health and disease could lead to new therapeutic strategies to 
modulate such differentiation process. 
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Figure legends: 
 
Fig. 1. MARS-seq and CyTOF® identifies rare CD123+CD33+ putative pre-DC. (A-E) 710 
sorted Lin(CD3/CD14/CD16/CD20/CD34)-HLA-DR+CD135+ PBMC (see Figure S1A for gating 
strategy) were subjected to MARS-seq. (A) tSNE plot of the 710 cells, colored by (left panel) 
clusters identified by tSNE + Seurat clustering (clusters labeled #1-#5), or colored by the relative 
signature score for (from left to right) pDC, cDC1 and CD2. (B) cMAP analysis showing the 
degree of enrichment for transcripts of pDC or cDC signature genes for the 5 tSNE/Seurat 
clusters. (C) Mpath analysis applied to the 5 tSNE/Seurat clusters defining their developmental 
relationship. (D) Principal component analysis (PCA) representation of the 710 cells highlighting 
the tSNE/Seurat clusters identified in (A). (E) Violin plots showing the expression of pDC and 
cDC signature genes for tSNE/Seurat pDC clusters (#1+#2, blue), the central cluster #4 (purple) 
and cDC clusters (#3+#5). Displayed genes were selected for their differential expression 
between the tSNE/Seurat clusters #4 (purple) and pDC (clusters #1+#2). Adjusted p values were 
calculated with the Kruskal-Wallis test followed by the Dunn’s multiple comparisons test. (F, G) 
tSNE plots of CyTOF data from CD45+Lin(CD7/CD14/CD15/CD16/CD19/CD34)-HLA-DR+ 
PBMC, (F) gates defining CD123+CD33+ cells and DC subsets, and (G) relative expression level 
of selected markers. (H) Subsets defined in Fig. 1F were overlaid onto 2D contour plots to for 
phenotypic comparison. 
 
Fig. 2. Characterization of human pre-DC. (A) Identification of pre-DC (purple), pDC (blue), 
cDC1 (red) and cDC2 (beige) within PBMC and spleen. (B) Expression of CD303, CD304, 
CD123 and CD11c by pre-DC and DC subsets. (C) Relative numbers of pre-DC in peripheral 
blood (n=6) and spleen (n=3). (D) Wright-Giemsa staining of blood pre-DC (left panels) and 
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pDC (right panels). (E) Representative electron micrographs showing morphological 
characteristics of pre-DC and pDC; boxed areas are shown at higher magnification below. 
Putative pre-DC exhibited thinner cytoplasm with homogeneously-distributed mitochondria (m) 
and relatively less rough endoplasmic reticulum (RER, arrowheads) compared to pDC. pDC 
exhibited an abundant cytoplasm, packed mitochondria and a well-developed cortical RER, 
organized in parallel cisterna at a pole of the cell (note the presence of the centriole (C) and 
microtubules (small arrows) near RER cisterna). (F) DC subset and pre-DC populations co-
cultured for 5 days with MS-5 feeder cells supplemented with FLT3L, GM-CSF and SCF were 
investigated for the presence of CD123+CD172α- pDC (blue), Clec9A+CADM1+ cDC1 (red) or 
CD172α+CD1c+ cDC2 (beige). (G) Detection of intracellular cytokine production by DC subsets 
and pre-DC following TLR stimulation. 2-D plots of IFN and IL-12p40 production by pDC 
(blue) and pre-DC (purple) are shown, alongside mean relative frequency of IFN+-, IL-12p40+- 
and TNF+- producing cells within pre-DC and DC subsets following exposure to LPS, 
LPS+IFN (L+I), polyI:C (pI:C), CL097 (CL) or CpG ODN2216 (CpG) (n=4). (H) Proliferation 
of naïve CD4+ T cells after 6 days of culture with allogenic CD123+CD33+ pre-DC or 
CD123+CD33- pDC (n=2). (I) Graphical representation of the frequency of pDC (upper panel) 
and pre-DC (lower panel) within CD45+ PBMC from control (Ctrl, n=11) and Pitt-Hopkins 
patients (PH, n=4). P-values calculated by Mann-Whitney test. 
Fig. 3. Identification of committed human pre-DC subsets. (A-B) Single-cell mRNAseq of 92 
sorted Lin(CD3/14/16/19/20)-HLA-DR+CD33+CD123+ cells (see Fig. S9A (not S9A – couldn’t 
see it) for the sort gating strategy). (A) cMAP enrichment score of cells for cDC1- or cDC2- 
specific signatures. (B) Mpath analysis showing the development relationship between cells 
defined as “unprimed” (central grey cluster) or cDC1- (green) and cDC2- (orange) primed in the 
cMAP analysis in (A). (C-E) 3D-PCA of Lin-HLA-DR+CD33+ PBMC, analyzed by flow 
cytometry. (C) Dot plot of PCA components 1-3 revealed 3 major cell clusters corresponding to 
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pre-DC (purple circle), CADM1+ cDC1 (red circle) and CD1c+ cDC2 (beige circle). Relative 
expression of CADM1, CD1c and CD123 is displayed. (D) Magnification of the intersect 
between pre-DC, cDC1 and cDC2 in the 3D-PCA plot showing the relative expression of 
CD45RA, BTLA, CD327, CD141 and CD5. Dashed black circle delineates the intermediate 
CD45RA+ population. (E) CD45RA/CD123 dot plots showing overlaid cell subsets defined in 
the 3D-PCA plot (far left panel) with the relative expression of BTLA, CD327, CD141 and CD5. 
(F) The Wanderlust dimension (early to dark events progressively switching from dark to clear) 
was overlaid onto the 3D-PCA and the CD45RA/CD123 dot plots of panels C-E. (G) Sequential 
gating of flow cytometric data starting from Live CD45+Lin(CD3/14/16/19/20)-CD34-HLA-DR+ 
PBMC to definition of putative pre-DC subsets among CD33+CD45RA+ cDC. (H) Pre-DC 
subsets co-cultured for 5 days on MS-5 feeder cells supplemented with FLT3L, GM-CSF and 
SCF were analyzed for their capacity to differentiate into Clec9A+CADM1+ cDC1 (red or 
CD1c+CD11c+ cDC2 (beige). (I) Morphology of sorted pre-DC and DC subsets visualized by 
SEM. 
Fig. 4. DC and pre-DC subset gene expression analysis. Microarray data from sorted DC and 
pre-DC subsets in Fig. 3 were analyzed by (A) 3D-PCA using probe-filtered genes (upper panel) 
or DEG (lower panel). For PCA dimension, the loading value was indicated as relative number. 
(B-D) Heat maps of DEG between (B) early pre-DC/pDC (C) early pre-DC/pre-cDC1/cDC1 and 
(D) early pre-DC/pre-cDC2/cDC2. (E) Profile analysis of all common DEGs between early pre-
DC, pre-cDC1, cDC1, pre-cDC2 and cDC2. (F) Expression level of CD327, CD22 and AXL 
proteins by DC and pre-DC subsets evaluated by flow cytometry. MFI are indicated. (G) Profile 
analysis of selected transcription factor-coding genes. 
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Fig. 5. Functional analysis of DC and pre-DC subsets. (A) Frequency of cytokine production 
by pre-DC and DC subsets upon TLR stimulation was measured by intracellular flow cytometry. 
Left panel shows dot plots of IFN, IL-12p40 and TNF production by pDC (blue), early pre-
DC (purple), pre-cDC2 (orange), cDC2 (beige), pre-cDC1 (green) and cDC1 (red); right panels 
show mean relative numbers of pre-DC and DC subset cells producing IFN+, IL-12p40+ or 
TNF+ in response to LPS, LPS+IFN (L+I), pI:C, CL097 (CL) or CpG ODN2216 (CpG) (n=4). 
(B) Expression level (MFI) of costimulatory molecules (CD40, CD80, CD83, CD86) by blood 
pre-DC and DC subsets (n=4). (C) Proliferation of naïve CD4+ T cells after 6 days of culture 
with allogenic pre-DC and DC subsets (n=3). 
 
Fig. 6. Unsupervised mapping of DC ontogeny using CyTOF. CyTOF data from (A, C) BM 
and (B, C) blood (PBMC) were analyzed using isoMAP dimensionality reduction to compare 
overall phenotypic relatedness of cell populations, and were automatically subdivided into 
clusters using the phenograph algorithm. (A, B) IsoMAP1-2 plots showing expression level of 
CDP-, pDC- and pre-DC/cDC-specific markers within (A) BM, and (B) blood 
Lin(CD3/CD7/CD14/CD15/CD19/CD34)-HLA-DR+CD123+ cells. (C) Phenotypic relationship 
of Lin-HLA-DR+, CD123hi BM marrow and CD123+ PBMC, showing progression from CDP 
(light blue) towards pDC (blue) or pre-DC (pink) in the BM, and the clear separation of pDC 
(blue) and pre-DC (pink) in the blood. Both in the BM (upper panels) and in the blood (lower 
panels), cells within the pre-DC phenograph clusters (#1 and #2 in the BM, and #6 in the blood) 
and cells within the pDC phenograph clusters (#3 and #4 in the BM, and #7 in the blood) were 
further analyzed by isoMAP to define pre-DC subsets (left panels, and Fig. S16C, D) and 
heterogeneity among pDC (right panels, and Fig. S16D, E). 
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